SureNano Science Ltd (TSE:SURE)
:SURE
Want to see TSE:SURE full AI Analyst Report?
Top Page
SureNano Science Ltd
(SURE)
Select Model
Select Model
Rating:45Neutral
Price Target:
C$0.22
▼(-28.33% Downside)
Action:UpgradedDate:04/24/26
The score is primarily weighed down by very weak financial performance (zero recent revenue, ongoing losses and cash burn, and negative equity despite no debt). Technical indicators are neutral-to-mixed and provide only limited support, while valuation is constrained by loss-making fundamentals and the absence of dividend yield.
Positive Factors
No reported debt / low apparent leverage
The absence of reported debt reduces near-term interest and refinancing pressures, preserving financial flexibility. For a cash-burning specialty chemicals firm, low leverage lowers default risk and leaves optionality to raise capital or pursue restructuring without immediate debt service constraints.
Negative Factors
Zero revenue across multiple years
A multi-year absence of revenue undermines the company’s ability to leverage its historical margin profile and validates structural demand or commercialization challenges. Without recurring sales, fixed costs persist, making profitability and sustainable growth unlikely without material business changes.
Read all positive and negative factors
Positive Factors
Negative Factors
No reported debt / low apparent leverage
The absence of reported debt reduces near-term interest and refinancing pressures, preserving financial flexibility. For a cash-burning specialty chemicals firm, low leverage lowers default risk and leaves optionality to raise capital or pursue restructuring without immediate debt service constraints.
Read all positive factors
SureNano Science Ltd (SURE) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$8.48M
Dividend YieldN/A
Average Volume (3M)666.00
Price to Earnings (P/E)―
Beta (1Y)-2.01
Revenue GrowthN/A
EPS Growth10.57%
CountryCA
EmployeesN/A
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)-0.01
Shares Outstanding33,907,800
10 Day Avg. Volume950
30 Day Avg. Volume666
Financial Highlights & Ratios
PEG Ratio0.37
Price to Book (P/B)-21.52
Price to Sales (P/S)0.00
P/FCF Ratio-10.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SureNano Science Ltd Business Overview & Revenue Model
Company Description
SureNano Science Ltd. operates as a nanotechnology supply company in Canada and Colorado, the United States. The company distributes SureNano surfactant, a ready-to-mix food-grade compound that provides the base for high performance hemp and canna...
How the Company Makes Money
null...
SureNano Science Ltd Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
14
Very Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Mar 2024 | Jun 2023 | Jun 2022 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 18.00K | 36.00K |
| Gross Profit | -1.88K | -2.50K | -2.50K | -3.75K | 16.51K | 34.66K |
| EBITDA | -407.27K | -57.09K | -277.39K | -380.27K | -1.12M | -81.59K |
| Net Income | -226.77K | -59.59K | -279.89K | -384.02K | -1.12M | -82.51K |
Balance Sheet | ||||||
| Total Assets | 1.20M | 54.27K | 153.11K | 317.61K | 686.44K | 966.81K |
| Cash, Cash Equivalents and Short-Term Investments | 1.17M | 23.49K | 134.80K | 276.99K | 667.09K | 929.01K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 34.16K | 134.04K | 173.29K | 57.90K | 36.49K | 17.32K |
| Stockholders Equity | 1.17M | -79.77K | -20.18K | 259.71K | 649.95K | 949.49K |
Cash Flow | ||||||
| Free Cash Flow | -208.53K | -161.31K | -142.19K | -403.63K | -669.76K | -102.99K |
| Operating Cash Flow | -208.53K | -161.31K | -142.19K | -383.63K | -669.76K | -102.99K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -6.47K | 0.00 | 0.00 |
| Financing Cash Flow | 1.39M | 50.00K | 0.00 | 0.00 | 407.85K | 1.03M |
SureNano Science Ltd Technical Analysis
Negative
0.30
Price Trends
0.27
Negative
0.27
Negative
0.20
Positive
Market Momentum
-0.02
Positive
38.81
Neutral
47.06
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:SURE, the sentiment is Negative. The current price of 0.3 is above the 20-day moving average (MA) of 0.25, above the 50-day MA of 0.27, and above the 200-day MA of 0.20, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 38.81 is Neutral, neither overbought nor oversold. The STOCH value of 47.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:SURE.
SureNano Science Ltd Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | C$2.79B | 22.34 | 28.32% | ― | 37.81% | 250.89% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
55 Neutral | C$304.36M | -3.44 | -414.40% | ― | 20.86% | -224.67% | |
48 Neutral | C$1.05B | -46.51 | -2.55% | 2.55% | 2.62% | 21.73% | |
45 Neutral | C$8.48M | -6.54 | ― | ― | ― | 10.57% | |
42 Neutral | C$12.69M | -2.61 | -86.94% | ― | -48.43% | -757.33% | |
42 Neutral | C$110.10M | -10.77 | -50.81% | ― | ― | 62.63% |
* Basic Materials Sector Average
TSE:SURE
SureNano Science Ltd
0.22
0.15
214.29%
TSE:CNO
California Nanotechnologies
0.27
-0.21
-43.75%
TSE:NANO
Nano One Materials
0.89
0.16
21.92%
TSE:VNP
5N Plus
32.77
25.99
383.33%
TSE:NEO
Neo Performance Materials Inc
25.30
14.08
125.51%
TSE:GMG
Graphene Manufacturing Group Ltd
2.44
1.78
269.70%
SureNano Science Ltd Corporate Events
Business Operations and StrategyExecutive/Board ChangesM&A Transactions
SureNano Buys GlucaPharm to Drive Next-Generation GLP-1 Drug Push
Positive
Feb 23, 2026
SureNano Science Ltd. has completed the acquisition of GlucaPharm Inc., gaining control of GEP44, a patented, second-generation GLP peptide that has shown significant weight-loss and blood-glucose benefits in preclinical studies with fewer gastroi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.